|
๐
|
Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.
11 auth.
T. Maher,
T. Corte,
A. Fischer,
M. Kreuter,
D. Lederer,
M. Molina-Molina,
...
J. Axmann,
K. Kirchgaessler,
K. Samara,
F. Gilberg,
V. Cottin
|
8 |
2020 |
8
๐
|
|
๐
|
Unmet needs in the treatment of idiopathic pulmonary fibrosisโinsights from patient chart review in five European countries
8 auth.
T. Maher,
M. Molina-Molina,
A. Russell,
F. Bonella,
S. Jouneau,
E. Ripamonti,
...
J. Axmann,
C. Vancheri
|
6 |
2017 |
6
๐
|
|
๐
|
Identifying Barriers to Idiopathic Pulmonary Fibrosis Treatment: A Survey of Patient and Physician Views
8 auth.
T. Maher,
J. Swigris,
M. Kreuter,
M. Wijsenbeek,
N. Cassidy,
L. Ireland,
...
J. Axmann,
S. Nathan
|
5 |
2018 |
5
๐
|
|
๐
|
Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: design of a double-blind, randomised, placebo-controlled phase II trial
9 auth.
T. Maher,
T. Corte,
A. Fischer,
M. Kreuter,
D. Lederer,
M. Molina-Molina,
...
J. Axmann,
K. Kirchgaessler,
V. Cottin
|
5 |
2018 |
5
๐
|
|
๐
|
A review of the challenges, learnings and future directions of home handheld spirometry in interstitial lung disease
11 auth.
T. Maher,
C. Schiffman,
M. Kreuter,
C. Moor,
S. Nathan,
J. Axmann,
...
P. Belloni,
M. Bengus,
F. Gilberg,
K. Kirchgaessler,
M. Wijsenbeek
|
4 |
2022 |
4
๐
|
|
๐
|
Pirfenidone Treatment in Individuals with Idiopathic Pulmonary Fibrosis: Impact of Timing of Treatment Initiation
12 auth.
T. Maher,
L. Lancaster,
S. Jouneau,
L. Morrison,
D. Lederer,
M. Molina-Molina,
...
E. Bendstrup,
K. Kirchgaessler,
F. Gilberg,
J. Axmann,
U. Petzinger,
P. Noble
|
4 |
2019 |
4
๐
|
|
๐
|
Pirfenidone in Unclassifiable Interstitial Lung Disease: A Subgroup Analysis by Concomitant Mycophenolate Mofetil and/or Previous Corticosteroid Use
8 auth.
M. Kreuter,
T. Maher,
T. Corte,
M. Molina-Molina,
J. Axmann,
F. Gilberg,
...
K. Kirchgaessler,
V. Cottin
|
2 |
2021 |
2
๐
|
|
๐
|
3TR: a pan-European cross-disease research consortium aimed at improving personalised biological treatment of asthma and COPD
29 auth.
C. Porsbjerg,
A. H. Maitlandโvan der Zee,
G. Brusselle,
G. Canonica,
A. Agustรญ,
R. Faner,
C. Vogelmeier,
M. Nawijn,
M. van den Berge,
F. Rusconi,
C. Pilette,
Valeria Ramiconi,
C. Coleman,
R. Chaudhuri,
K. Chung,
...
J. Wedzicha,
S. Saglani,
M. P. van der Schee,
L. Heaney,
A. Bourdin,
G. Roberts,
R. Djukanoviฤ,
P. Kuna,
M. Kupczyk,
J. Axmann,
H. Staudinger,
G. Clarke,
S. Dahlรฉn,
C. Brightling
|
2 |
2021 |
2
๐
|
|
๐
|
Late Breaking Abstract - Phase II trial of pirfenidone in patients with progressive fibrosing unclassifiable ILD (uILD)
11 auth.
T. Maher,
T. Corte,
A. Fischer,
M. Kreuter,
D. Lederer,
M. Molina-Molina,
...
J. Axmann,
K. Kirchgaessler,
K. Samara,
F. Gilberg,
V. Cottin
|
1 |
2019 |
1
๐
|
